Drug Marketing Firms, Manufacturers Will Be Equally Responsible For Medicine Quality

New Delhi : Pharmaceutical companies that are marketing medicines sourced from contract manufacturers or through marketing tie-ups will soon be equally responsible as the manufacturer for the quality of the drug sold in India.

Union Health Ministry has notified changes in the rule that governs regulation of drug manufacturing and marketing – Drugs and Cosmetics Rules – to treat marketer at par with the manufacturer when it comes to the quality of medicines as well as other regulatory compliances. A government notification on February 11 says that the new rule will come into force from March 1, 2021.

Sourcing of medicines from manufacturers is a common practice followed by big and small companies alike in India. Existence of pharmaceutical manufacturing hubs like Baddi in Himachal Pradesh is primarily because dozens of standalone drug manufacturing facilities in the hill states are able to custom produce the medicines for companies that have pan-India marketing network. The manufacturers also supply medicines to standalone and region-specific marketing firms that sell their own brands by generating local prescriptions. The new rule will make such marketing firms more accountable.

The Drugs and Cosmetics (Amendment) Rules, 2020  defines “Marketer” as a person who as an agent or in any other capacity adopts any drug manufactured by another manufacturer under an agreement for marketing of such drug by labeling or affixing his name on the label of the drug with a view for its sale and distribution.

It says that such marketing firms will not be allowed to label or brand any medicines without an agreement prescribed under the drug laws. It also says that such marketers, who sell or distribute drugs shall be responsible for quality of that drug as well as other regulatory compliances along with the manufacturer under the rules.

While the rule insists for display of the name of the marketer of the drug and its address on the packs, it permits display of just the name of the marketing firm if the drug is contained in an ampoule or a similar small container. The draft notification inviting public comments on the proposed changes was issued in June 2019.

  • Related Posts

    ICMR mandates clinical trials to focus on Indian demography, lifestyle

    New Delhi: Most medicines prescribed in India today are based on clinical trials conducted in Western countries. But Indian bodies, diets, and lifestyles are not the same. Prompted by this,…

    India’s Medical Devices Market Is Set To Hit $50 Billion By 2030: Rubix Report

    New Delhi:  India’s medical devices industry is on a remarkable growth trajectory, with projections indicating it will reach $50.1 billion by 2030, according to a recent report from Rubix Industry…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ICMR mandates clinical trials to focus on Indian demography, lifestyle

    ICMR mandates clinical trials to focus on Indian demography, lifestyle

    India’s Medical Devices Market Is Set To Hit $50 Billion By 2030: Rubix Report

    India’s Medical Devices Market Is Set To Hit $50 Billion By 2030: Rubix Report

    Muradnagar Police Bust Fake Liver-52 DS Herbal Medicine Racket: Three Arrested

    Muradnagar Police Bust Fake Liver-52 DS Herbal Medicine Racket: Three Arrested

    Massive Eskuf haul seized from train in Agartala

    Massive Eskuf haul seized from train in Agartala

    Vadodara Police Seize Illegal Steroids and Testosterone Injections from Russia and Austria in Bodybuilding Shop Raid

    Vadodara Police Seize Illegal Steroids and Testosterone Injections from Russia and Austria in Bodybuilding Shop Raid

    35 drugs manufactured in Telangana fail CDSCO quality checks

    35 drugs manufactured in Telangana fail CDSCO quality checks